The question that comes to mind when one considers the risks of a clinical trial is, “Why would anyone agree to participate?” Interviews with trial volunteers and their family members make clear that often it is the appeal of discovering something new and unknown.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018; 20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Zareen Zaidi, MD, PhD, Daniele Ölveczky, MD, MS, Nicole A. Perez, PhD, Paolo C. Martin, PhD, Andres Fernandez, MD, MSEd, Philicia Duncan, MD, and Hannah L. Anderson, MBA
This article canvasses ways to help trainees cultivate discernment and action in response to inequity.
AMA J Ethics. 2024; 26(1):E12-20. doi:
10.1001/amajethics.2024.12.
Alexandre White, PhD and Jeremy A. Greene, MD, PhD
Teaching and learning patient advocacy in academic health centers requires critical engagement with social, political, historical, and cultural conceptions of racial difference.
AMA J Ethics. 2024; 26(1):E62-67. doi:
10.1001/amajethics.2024.62.
S. Michelle Ogunwole, MD, PhD and Francheska D. Starks, PhD
Testimonial injustice is an expression of racism that uses identity to undermine individuals’ credibility as authoritative “knowers” of their own bodies, selves, and experiences.
AMA J Ethics. 2024; 26(1):E72-83. doi:
10.1001/amajethics.2024.72.
Dr Lisa Fuller joins Ethics Talk to discuss her article: “How Should Organizations and Clinicians Help Marginalized Patients Manage Loneliness as a Harm of Climate Change?”